KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Common Equity (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Common Equity data on record, last reported at $5.3 million in Q4 2025.

  • For Q4 2025, Common Equity fell 98.94% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, down 98.94%, while the annual FY2025 figure was $5.3 million, 98.94% down from the prior year.
  • Common Equity reached $5.3 million in Q4 2025 per PACB's latest filing, down from $36.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $840.8 million in Q3 2021 and bottomed at $5.3 million in Q4 2025.
  • Average Common Equity over 5 years is $493.6 million, with a median of $594.7 million recorded in 2022.
  • Peak YoY movement for Common Equity: soared 549.29% in 2021, then tumbled 98.94% in 2025.
  • A 5-year view of Common Equity shows it stood at $791.0 million in 2021, then dropped by 28.84% to $562.9 million in 2022, then grew by 24.59% to $701.3 million in 2023, then fell by 27.76% to $506.6 million in 2024, then crashed by 98.94% to $5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $5.3 million in Q4 2025, $36.1 million in Q3 2025, and $61.5 million in Q2 2025.